Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Thiazolidinediones Modulate the Expression of β-Catenin and Other Cell-Cycle Regulatory Proteins by Targeting the F-Box Proteins of Skp1-Cul1-F-box Protein E3 Ubiquitin Ligase Independently of Peroxisome Proliferator-Activated Receptor γ

Shuo Wei, Li-Fang Lin, Chih-Cheng Yang, Yu-Chieh Wang, Geen-Dong Chang, Hungwen Chen and Ching-Shih Chen
Molecular Pharmacology September 2007, 72 (3) 725-733; DOI: https://doi.org/10.1124/mol.107.035287
Shuo Wei
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li-Fang Lin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chih-Cheng Yang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu-Chieh Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geen-Dong Chang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hungwen Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ching-Shih Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Considering the role of aberrant β-catenin signaling in tumorigenesis, we investigated the mechanism by which the peroxisome proliferator-activated receptor γ (PPARγ) agonist troglitazone facilitated β-catenin down-regulation. We demonstrate that troglitazone and its more potent PPARγ-inactive analogs Δ2TG and STG28 mediated the proteasomal degradation of β-catenin in prostate cancer cells by up-regulating the expression of β-transducin repeat-containing protein (β-TrCP), an F-box component of the Skp1-Cul1-F-box protein E3 ubiquitin ligase. Evidence indicates that although small interfering RNA-mediated β-TrCP knockdown protected cells against STG28-facilitated β-catenin ablation, ectopic β-TrCP expression enhanced the degradation. The involvement of β-TrCP in β-catenin degradation was also corroborated by the pull-down analysis and the concurrent down-regulation of known β-TrCP substrates examined, including Wee1, Iκβα, cdc25A, and nuclear factor-κB/p105. Furthermore, glycogen synthase kinase-3β represented a key regulator in the effect of these thiazolidinedione derivatives on β-catenin proteolysis even though these agents increased its phosphorylation level. It is noteworthy that this drug-induced β-TrCP up-regulation was accompanied by the concomitant down-regulation of Skp2 and Fbw7, thereby affecting many of the target proteins of these two F-box proteins (such as p27 and cyclin E). As a consequence, the ability of troglitazone to target these F-box proteins provides a molecular basis to account for its reported effect on modulating the expression of aforementioned cell-cycle regulatory proteins. Despite this complicated mode of pharmacological actions, normal prostate epithelial cells, relative to LNCaP cells, were less susceptible to the effects of STG28 on modulating the expression of β-catenin and β-TrCP, suggesting the translation potential of using STG28 as a scaffold to develop more potent chemopreventive agents.

Footnotes

  • This work was supported by National Institutes of Health grant CA112250, Department of Defense Prostate Cancer Research Program Award W81XWH-05-1-0089, and a Prostate Cancer Foundation Competitive Award.

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

  • doi:10.1124/mol.107.035287.

  • ABBREVIATIONS: PPARγ, peroxisome proliferator-activated receptor γ; SCF, Skp1-Cul1-F-box protein; β-TrCP, β-transducin repeat-containing protein; GSK3β, glycogen synthase kinase 3β; PrECs, normal prostate epithelial cells; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; GST, glutathione transferase; APC, adenomatous polyposis coli; siRNA, small interfering RNA; DMSO, dimethyl sulfoxide; HA, hemagglutinin; NFκB, nuclear factor κB; FBS, fetal bovine serum; PCR, polymerase chain reaction; TBST, Tris-buffered saline/Tween 20; PI, propidium iodide; PBS, phosphate-buffered saline; TG, troglitazone; MG132, N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal; SB216763, 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; ZVAD-fmk, benzyloxycarbonyl-Val-Ala-Asp fluoro-methylketone; E-64, N-(trans-epoxysuccinyl)-l-leucine 4-guanidinobutylamide; GW9662, 2-chloro-5-nitro-N-phenyl-benzamide.

    • Received February 17, 2007.
    • Accepted June 14, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 72 (3)
Molecular Pharmacology
Vol. 72, Issue 3
1 Sep 2007
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Thiazolidinediones Modulate the Expression of β-Catenin and Other Cell-Cycle Regulatory Proteins by Targeting the F-Box Proteins of Skp1-Cul1-F-box Protein E3 Ubiquitin Ligase Independently of Peroxisome Proliferator-Activated Receptor γ
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Thiazolidinediones Modulate the Expression of β-Catenin and Other Cell-Cycle Regulatory Proteins by Targeting the F-Box Proteins of Skp1-Cul1-F-box Protein E3 Ubiquitin Ligase Independently of Peroxisome Proliferator-Activated Receptor γ

Shuo Wei, Li-Fang Lin, Chih-Cheng Yang, Yu-Chieh Wang, Geen-Dong Chang, Hungwen Chen and Ching-Shih Chen
Molecular Pharmacology September 1, 2007, 72 (3) 725-733; DOI: https://doi.org/10.1124/mol.107.035287

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Thiazolidinediones Modulate the Expression of β-Catenin and Other Cell-Cycle Regulatory Proteins by Targeting the F-Box Proteins of Skp1-Cul1-F-box Protein E3 Ubiquitin Ligase Independently of Peroxisome Proliferator-Activated Receptor γ

Shuo Wei, Li-Fang Lin, Chih-Cheng Yang, Yu-Chieh Wang, Geen-Dong Chang, Hungwen Chen and Ching-Shih Chen
Molecular Pharmacology September 1, 2007, 72 (3) 725-733; DOI: https://doi.org/10.1124/mol.107.035287
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Fatty Acid Amide Hydrolase in Cisplatin Nephrotoxicity
  • Use-Dependent Relief of A-887826 Inhibition
  • Benzbromarone Relaxes Airway Smooth Muscle via BK Activation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics